Svelte Medical Systems Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Employees
-
22
- Latest Deal Type
-
M&A
Svelte Medical Systems General Information
Description
Developer of drug-eluting coronary stent-on-a-wire Integrated delivery system designed to treat coronary artery disease. The company's device incorporates specialized guide wire tip technology and its proprietary balloon enhances direct stenting and navigates coronary arteries like a guide wire, thereby eliminating the need for additional guide wires and balloons in most cases, enabling patients to experience better clinical outcomes, enhanced comfort and reduced time and cost of procedures.
Contact Information
Website
www.sveltemedical.comCorporate Office
- 675 Central Avenue
- New Providence, NJ 07974
- United States
Corporate Office
- 675 Central Avenue
- New Providence, NJ 07974
- United States
Svelte Medical Systems Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 27-Apr-2026 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Private | 01-Aug-2021 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series C) | 23-Apr-2021 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B3) | 21-Jan-2019 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series B2) | 21-Nov-2017 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series B1) | 25-Jul-2016 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 10-Mar-2014 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 14-Dec-2011 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A1) | 07-Dec-2009 | $6M | $20M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 15-May-2009 | $14M | $14M | Completed | Generating Revenue |
Svelte Medical Systems Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B3 | ||||||||
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series A1 | 10,848 | $0.001000 | 8% | $1000 | $1000 | 1x | $1000 | 0.97% |
| Series A | 42,296 | $0.001000 | 8% | $1000 | $1000 | 1x | $1000 | 3.77% |
Svelte Medical Systems Comparisons
Industry
Financing
Details
Svelte Medical Systems Competitors (7)
One of Svelte Medical Systems’s 7 competitors is DexCom, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DexCom | Formerly VC-backed | San Diego, CA | ||||
| Wallaby Medical | Venture Capital-Backed | Shanghai, China | ||||
| Biotronik | Corporate Backed or Acquired | Berlin, Germany | ||||
| R3 Vascular | Venture Capital-Backed | Mountain View, CA | ||||
| REVA Medical | Venture Capital-Backed | San Diego, CA |
Svelte Medical Systems Patents
Svelte Medical Systems Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2651346-A2 | A stent delivery catheter | Inactive | 15-Dec-2010 | ||
| US-20120158116-A1 | Means and method for preventing embolization of drug eluting stents | Active | 15-Dec-2010 | ||
| US-9056025-B2 | Means and method for preventing embolization of drug eluting stents | Inactive | 15-Dec-2010 | ||
| WO-2012082598-A2 | Means and method for preventing embolization of drug eluting stents | Inactive | 15-Dec-2010 | ||
| WO-2012082598-A3 | Means and method for preventing embolization of drug eluting stents | Inactive | 15-Dec-2010 | A61F2/958 |
Svelte Medical Systems Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Svelte Medical Systems Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Apjohn Ventures | Venture Capital | Minority | ||
| CNF Investments | PE/Buyout | Minority | ||
| Dempsey Ventures | Family Office | Minority | ||
| New Science Ventures | Venture Capital | Minority | ||
| Norwich Ventures | Venture Capital | Minority |
Svelte Medical Systems Investments (1)
Svelte Medical Systems’s most recent deal was a Early Stage VC with Ostial Solutions for . The deal was made on 08-Sep-2010.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ostial Solutions | 08-Sep-2010 | Early Stage VC | Therapeutic Devices |
Svelte Medical Systems FAQs
-
When was Svelte Medical Systems founded?
Svelte Medical Systems was founded in 2007.
-
Where is Svelte Medical Systems headquartered?
Svelte Medical Systems is headquartered in New Providence, NJ.
-
What is the size of Svelte Medical Systems?
Svelte Medical Systems has 22 total employees.
-
What industry is Svelte Medical Systems in?
Svelte Medical Systems’s primary industry is Therapeutic Devices.
-
Is Svelte Medical Systems a private or public company?
Svelte Medical Systems is a Private company.
-
What is Svelte Medical Systems’s current revenue?
The current revenue for Svelte Medical Systems is .
-
How much funding has Svelte Medical Systems raised over time?
Svelte Medical Systems has raised $172M.
-
Who are Svelte Medical Systems’s investors?
Apjohn Ventures, CNF Investments, Dempsey Ventures, New Science Ventures, and Norwich Ventures are 5 of 8 investors who have invested in Svelte Medical Systems.
-
Who are Svelte Medical Systems’s competitors?
DexCom, Wallaby Medical, Biotronik, R3 Vascular, and REVA Medical are some of the 7 competitors of Svelte Medical Systems.
-
When was Svelte Medical Systems acquired?
Svelte Medical Systems was acquired on 27-Apr-2026.
-
Who acquired Svelte Medical Systems?
Svelte Medical Systems was acquired by Advanced Bifurcation Systems.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
